glp-1 lafayette Agonists: A Comprehensive Overview GLP-1 Injections | Medical Weight
Description
Food & Drug Administration, 2021 titration schedule, boxed thyroid C-cell tumor warning, contraindications
Orforglipron significantly reduced HbA1c to 2.1% in a phase II clinical trial assessing its use in T2DM, while dulaglutide achieved 1.1% and a placebo achieved 0.43% [106]
Rapid weight loss can increase vulnerability if dietary intake is not adequately structured
This would help answer the question of whether previously reported negative outcomes in other trials were a drug-specific retinal toxicity of the GLP-1/GIP receptor agonists vs
